Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $49,399.84 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 6,301 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $7.84, for a total value of $49,399.84. Following the completion of the transaction, the insider now directly owns 204,563 shares of the company’s stock, valued at $1,603,773.92. This represents a 2.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39.

Ocular Therapeutix Price Performance

Shares of OCUL stock opened at $7.82 on Wednesday. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.77. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock has a 50 day simple moving average of $8.61 and a two-hundred day simple moving average of $9.02.

Institutional Trading of Ocular Therapeutix

Several hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its stake in Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after acquiring an additional 660,080 shares in the last quarter. Patient Square Capital LP bought a new position in shares of Ocular Therapeutix during the 3rd quarter worth about $2,049,000. Polar Asset Management Partners Inc. acquired a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at about $4,288,000. SG Americas Securities LLC bought a new stake in Ocular Therapeutix in the 3rd quarter valued at about $393,000. Finally, FMR LLC increased its position in Ocular Therapeutix by 7,098.7% in the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock valued at $3,779,000 after buying an additional 428,335 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on OCUL shares. Scotiabank assumed coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.